Axovant Sciences Stock Price, News & Analysis (NASDAQ:AXON)

$2.03 -0.03 (-1.46 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$2.03
Today's Range$2.00 - $2.06
52-Week Range$2.00 - $27.98
Volume1.12 million shs
Average Volume2.08 million shs
Market Capitalization$215.47 million
P/E Ratio-0.88
Dividend YieldN/A
BetaN/A

About Axovant Sciences (NASDAQ:AXON)

Axovant Sciences logoAxovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AXON
CUSIPN/A
Phone+44-1295-5950

Debt

Debt-to-Equity Ratio0.34%
Current Ratio5.94%
Quick Ratio5.94%

Price-To-Earnings

Trailing P/E Ratio-0.878787878787879
Forward P/E Ratio-0.94
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book1.61

Profitability

Trailing EPS($2.31)
Net Income$-180,950,000.00
Net MarginsN/A
Return on Equity-146.93%
Return on Assets-97.18%

Miscellaneous

Employees69
Outstanding Shares107,710,000

Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd (NASDAQ:AXON) released its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.09. View Axovant Sciences' Earnings History.

When will Axovant Sciences make its next earnings announcement?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Axovant Sciences.

Where is Axovant Sciences' stock going? Where will Axovant Sciences' stock price be in 2018?

10 equities research analysts have issued 1 year target prices for Axovant Sciences' stock. Their forecasts range from $2.50 to $30.00. On average, they expect Axovant Sciences' stock price to reach $14.75 in the next twelve months. View Analyst Ratings for Axovant Sciences.

What are Wall Street analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:

  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (11/9/2017)
  • 2. HC Wainwright analysts commented, "We hosted a conference call with a medical physicist on October 17, 2017. The consultant highlighted a number of key benefits associated with ViewRay’s MRI-Cobalt and MRI-LINAC as well as main differences between ViewRay’s low-T MRIdian technology and competitor Elekta’s yet-to-be approved High- T Unity system. Replay information available upon request. KeyPoints High-T vs. Low-T. While in the context of a diagnosis, a high-T system would surely lead to greater image resolution, the low-T system appears more suitable in the treatment phase where the key lies in the ability to locate the patient’s tumor in a dynamic way. Image quality, it turns out, can be improved through various techniques according to our consultant." (10/19/2017)
  • 3. Piper Jaffray Companies analysts commented, "We see these results as mixed but positive for the company's first foray into this under-studied disease. First off, nelo' did appear safe/well tolerated, which was a non-zero risk in this population. In addition, the study suggested some benefit on ADL and motor function ' not exactly what we were expecting, but if replicated could address a key unmet need in DLB especially. We didn't yet see improvement on visual hallucinations but longer dosing in more patients may be helpful here. We'll await full results around mid'17, and remain optimistic these results and/or the DLB-RBD study will inform a Phase III program for nelo' in at least one LBD symptom complex. For now, nelo' is upside to our valuation and we remain focused on the pivotal programs for RVT-101 in AD and DLB." (2/13/2017)

Who are some of Axovant Sciences' key competitors?

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:

  • Marion McCourt, President, Chief Operating Officer (Age 57)
  • David T. Hung M.D., Chief Executive Officer, Director (Age 60)
  • Gregory M. Weinhoff M.D., Chief Financial Officer (Age 46)
  • Vivek Ramaswamy, Director, Chief Executive Officer - Roivant Sciences (Age 31)
  • Mark Altmeyer, President of Axovant Sciences GmbH and Chief Commercial Officer (Age 56)
  • Eric Floyd Ph.D., Senior Vice President - Regulatory Affairs
  • Ilise Lombardo M.D., Senior Vice President - Clinical Research
  • Thomas Templeman Ph.D., Senior Vice President - Pharmaceutical Operations and Quality Assurance
  • Mark Wadley, Senior Vice President, US Business
  • Samina Bari, Vice President - Corporate Communications

When did Axovant Sciences IPO?

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Axovant Sciences stock?

Axovant Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Hikari Power Ltd (0.07%). Company insiders that own Axovant Sciences stock include David Hung, Mark Altmeyer and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

Who bought Axovant Sciences stock? Who is buying Axovant Sciences stock?

Axovant Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Hikari Power Ltd. Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, Mark Altmeyer and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.

How do I buy Axovant Sciences stock?

Shares of Axovant Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of Axovant Sciences stock can currently be purchased for approximately $2.03.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $215.47 million. The biotechnology company earns $-180,950,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Axovant Sciences employs 69 workers across the globe.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 Bedford Row, LONDON, WC1R 4JS, United Kingdom. The biotechnology company can be reached via phone at +44-1295-5950.


MarketBeat Community Rating for Axovant Sciences (AXON)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Axovant Sciences (NASDAQ:AXON) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.402.402.362.80
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.75$14.80$14.68$29.85
Price Target Upside: 549.78% upside184.07% upside149.69% upside35.07% upside

Axovant Sciences (NASDAQ:AXON) Consensus Price Target History

Price Target History for Axovant Sciences (NASDAQ:AXON)

Axovant Sciences (NASDAQ:AXON) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018CowenDowngradeOutperform -> Market PerformHighView Rating Details
1/10/2018Chardan CapitalUpgradeSell -> Neutral$2.50 -> $2.50LowView Rating Details
12/21/2017Jefferies GroupDowngradeBuy -> Hold$6.00HighView Rating Details
12/1/2017HC WainwrightReiterated RatingBuy$11.00MediumView Rating Details
11/12/2017OppenheimerReiterated RatingHoldN/AView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingHoldN/AView Rating Details
11/1/2017Robert W. BairdReiterated RatingHold$6.00N/AView Rating Details
9/26/2017Evercore ISIReiterated RatingOutperform$30.00 -> $9.00HighView Rating Details
9/26/2017JMP SecuritiesReiterated RatingOutperform$36.00 -> $19.00N/AView Rating Details
6/14/2017CIBCBoost Price TargetOutperform -> Outperform$26.00 -> $30.00HighView Rating Details
12/20/2016LaidlawInitiated CoverageSell$7.50N/AView Rating Details
6/30/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Axovant Sciences (NASDAQ:AXON) Earnings History and Estimates Chart

Earnings by Quarter for Axovant Sciences (NASDAQ:AXON)

Axovant Sciences (NASDAQ AXON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018        
11/2/2017Q2 2018($0.55)($0.64)ViewN/AView Earnings Details
8/7/2017Q1 2018($0.53)($0.65)ViewN/AView Earnings Details
6/13/20173/31/2017($0.51)($0.53)ViewN/AView Earnings Details
2/14/2017Q3($0.45)($0.48)ViewN/AView Earnings Details
11/7/2016Q2 2017($0.40)($0.43)ViewN/AView Earnings Details
8/15/2016Q1($0.36)($0.38)ViewN/AView Earnings Details
6/6/2016Q4 2016($0.30)($0.30)ViewN/AView Earnings Details
2/9/2016Q315($0.15)($0.64)ViewN/AView Earnings Details
11/2/2015Q215($0.24)($0.12)ViewN/AView Earnings Details
8/11/2015Q115($0.10)($0.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Axovant Sciences (NASDAQ:AXON) Earnings Estimates

2018 EPS Consensus Estimate: ($1.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.55)($0.53)($0.54)
Q2 20182($0.65)($0.52)($0.59)
Q3 20182($0.54)($0.22)($0.38)
Q4 20182($0.51)($0.26)($0.39)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Axovant Sciences (NASDAQ:AXON)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Axovant Sciences (NASDAQ AXON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 72.40%
Institutional Ownership Percentage: 96.93%
Insider Trades by Quarter for Axovant Sciences (NASDAQ:AXON)
Institutional Ownership by Quarter for Axovant Sciences (NASDAQ:AXON)

Axovant Sciences (NASDAQ AXON) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2017David HungInsiderBuy539,375$18.54$10,000,012.50539,375View SEC Filing  
4/17/2017W Anthony VernonDirectorBuy53,937$18.54$999,991.9853,937View SEC Filing  
3/10/2016Mark AltmeyerInsiderBuy2,300$11.14$25,622.002,300View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Axovant Sciences (NASDAQ AXON) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.48 Per Share Brokerages Anticipate Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - January 15 at 1:10 AM
CBMG Giving Back Its Gains, ARNA To Report Data In Q1, AXON Continues To Fall - NasdaqCBMG Giving Back Its Gains, ARNA To Report Data In Q1, AXON Continues To Fall - Nasdaq
www.nasdaq.com - January 12 at 3:38 PM
Axovant Sciences (AXON) Rating Lowered to Market Perform at CowenAxovant Sciences (AXON) Rating Lowered to Market Perform at Cowen
www.americanbankingnews.com - January 12 at 8:02 AM
After A Freefall In Axovant Shares, Chardan UpgradesAfter A Freefall In Axovant Shares, Chardan Upgrades
finance.yahoo.com - January 10 at 3:41 PM
Implied Volatility Surging for Axovant Sciences (AXON) Stock OptionsImplied Volatility Surging for Axovant Sciences (AXON) Stock Options
finance.yahoo.com - January 10 at 11:22 AM
Heres Why Axovant Sciences Dropped TodayHere's Why Axovant Sciences Dropped Today
www.fool.com - January 9 at 11:08 AM
GoPro, Axovant Sciences Plunge into Monday’s 52-Week Low ClubGoPro, Axovant Sciences Plunge into Monday’s 52-Week Low Club
www.marketwatch.com - January 9 at 11:08 AM
CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin StudyCORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
finance.yahoo.com - January 9 at 11:08 AM
38 Stocks Moving In Mondays Mid-Day Session - Benzinga38 Stocks Moving In Monday's Mid-Day Session - Benzinga
www.benzinga.com - January 8 at 3:46 PM
Axovant Will No Longer Develop Lead Dementia Drug - Wall Street JournalAxovant Will No Longer Develop Lead Dementia Drug - Wall Street Journal
www.wsj.com - January 8 at 3:46 PM
Axovant Crumbles Following Alzheimer’s Study UpdateAxovant Crumbles Following Alzheimer’s Study Update
finance.yahoo.com - January 8 at 3:46 PM
[$$] Axovant Will No Longer Develop Lead Dementia Drug[$$] Axovant Will No Longer Develop Lead Dementia Drug
finance.yahoo.com - January 8 at 3:46 PM
Here's Why Axovant Sciences Dropped TodayHere's Why Axovant Sciences Dropped Today
finance.yahoo.com - January 8 at 3:46 PM
Roivant-backed company partners with DCRIRoivant-backed company partners with DCRI
finance.yahoo.com - January 8 at 3:46 PM
BUZZ-Axovant Sciences: Slumps as key drug program scrappedBUZZ-Axovant Sciences: Slumps as key drug program scrapped
www.cnbc.com - January 8 at 8:39 AM
Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin StudyAxovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
finance.yahoo.com - January 8 at 8:39 AM
Axovant to scrap intepirdine program after dementia trial failsAxovant to scrap intepirdine program after dementia trial fails
finance.yahoo.com - January 8 at 8:39 AM
Axovant shares plunge after key drug programme scrappedAxovant shares plunge after key drug programme scrapped
finance.yahoo.com - January 8 at 8:39 AM
Axovant Sciences Target of Unusually High Options Trading (AXON)Axovant Sciences Target of Unusually High Options Trading (AXON)
www.americanbankingnews.com - January 7 at 2:38 AM
Axovant Sciences Ltd (AXON) Receives Average Recommendation of "Hold" from BrokeragesAxovant Sciences Ltd (AXON) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 1 at 7:54 AM
Stock Traders Buy High Volume of Call Options on Axovant Sciences (AXON)Stock Traders Buy High Volume of Call Options on Axovant Sciences (AXON)
www.americanbankingnews.com - January 1 at 2:28 AM
Critical Review: Axovant Sciences (AXON) versus The CompetitionCritical Review: Axovant Sciences (AXON) versus The Competition
www.americanbankingnews.com - December 30 at 3:16 PM
Axovant Sciences Ltd (AXON) Expected to Announce Earnings of -$0.49 Per ShareAxovant Sciences Ltd (AXON) Expected to Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - December 29 at 5:26 AM
John Carroll - BenzingaJohn Carroll - Benzinga
www.benzinga.com - December 28 at 4:27 PM
Axovant Sciences (AXON) Downgraded to Hold at Jefferies GroupAxovant Sciences (AXON) Downgraded to Hold at Jefferies Group
www.americanbankingnews.com - December 21 at 5:56 PM
Axovant Sciences Ltd (AXON) Sees Large Decrease in Short InterestAxovant Sciences Ltd (AXON) Sees Large Decrease in Short Interest
www.americanbankingnews.com - December 15 at 3:08 AM
Axovant Sciences (AXON) versus The Competition Head to Head SurveyAxovant Sciences (AXON) versus The Competition Head to Head Survey
www.americanbankingnews.com - December 12 at 7:34 PM
Axovant Sciences Ltd (AXON) Receives Consensus Rating of "Hold" from AnalystsAxovant Sciences Ltd (AXON) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 7 at 7:56 AM
Contrasting Axovant Sciences (AXON) & Its RivalsContrasting Axovant Sciences (AXON) & Its Rivals
www.americanbankingnews.com - December 2 at 5:32 PM
Axovant Sciences (AXON) Cut to "Sell" at BidaskClubAxovant Sciences (AXON) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - December 2 at 7:20 AM
Axovant Sciences (AXON) Buy Rating Reiterated at HC WainwrightAxovant Sciences' (AXON) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - December 1 at 5:38 PM
Axovant Sciences Ltd. (AXON) Raised to "Hold" at BidaskClubAxovant Sciences Ltd. (AXON) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - November 23 at 12:08 AM
Axovant Sciences Ltd. to Post Q3 2018 Earnings of ($0.54) Per Share, Oppenheimer Holdings Forecasts (AXON)Axovant Sciences Ltd. to Post Q3 2018 Earnings of ($0.54) Per Share, Oppenheimer Holdings Forecasts (AXON)
www.americanbankingnews.com - November 15 at 12:00 PM
Axovant Sciences Appoints Dr. Gary P. Pisano to Board of Directors - PR Newswire (press release)Axovant Sciences Appoints Dr. Gary P. Pisano to Board of Directors - PR Newswire (press release)
www.prnewswire.com - May 13 at 2:41 PM
Volatile Market Flatlines Biotech IPOs - BenzingaVolatile Market Flatlines Biotech IPOs - Benzinga
www.benzinga.com - February 12 at 12:40 PM
Oversold Conditions For Axovant Sciences (AXON) - NasdaqOversold Conditions For Axovant Sciences (AXON) - Nasdaq
www.nasdaq.com - February 6 at 11:54 AM
Heres Chardans Conviction Sell On Axovant - BenzingaHere's Chardan's 'Conviction Sell' On Axovant - Benzinga
www.benzinga.com - February 4 at 12:14 PM
Pfizer Halts Drug Trial, Investors Flee AxovantPfizer Halts Drug Trial, Investors Flee Axovant
www.forbes.com - February 2 at 10:43 AM
Why Axovant Sciences Skyrocketed 56% in NovemberWhy Axovant Sciences Skyrocketed 56% in November
www.fool.com - December 3 at 7:00 AM
AXOVANT SCIENCES LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and FinanAXOVANT SCIENCES LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Finan
biz.yahoo.com - November 2 at 4:22 PM
Q2 2015 Axovant Sciences Ltd Earnings Release - After Market CloseQ2 2015 Axovant Sciences Ltd Earnings Release - After Market Close
biz.yahoo.com - November 2 at 7:07 AM

SEC Filings

Axovant Sciences (NASDAQ:AXON) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Axovant Sciences (NASDAQ:AXON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Axovant Sciences (NASDAQ AXON) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.